doxefazepam doxefazepam doxefazepam (marketed under brand name doxans) is a benzodiazepine medication it possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. it is used therapeutically as a hypnotic. according to babbini and colleagues in 1975, this derivative of flurazepam was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals. doxefazepamclinical dataroutes ofadministrationoralatc coden05cd12 (who) legal statuslegal status ca: schedule iv us: schedule iv pharmacokinetic datametabolismhepaticelimination half-life3-4 hoursexcretionrenalidentifiers iupac name 9-chloro-6-(2-fluorophenyl)-4-hydroxy-2-(2-hydroxyethyl)-2,5-diazabicycloundeca-5,8,10,12-tetraen-3-one cas number40762-15-0 npubchem cid38668chemspider35431 yunii231rv72c8lkeggd07327 ychemblchembl64677 ycomptox dashboard (epa)dtxsid2020551 chemical and physical dataformulac17h14clfn2o3molar mass348.8 g·mol−13d model (jsmol)interactive image smiles fc1=cc=cc=c1c2=nc(c(n(cco)c3=c2c=c(c=c3)cl)=o)o inchi inchi=1s/c17h14clfn2o3/c18-10-5-6-14-12(9-10)15(11-3-1-2-4-13(11)19)20-16(23)17(24)21(14)7-8-22/h1-6,9,16,22-23h,7-8h2 ykey:vojlelrqlpenhl-uhfffaoysa-n y ny (what is this?) it was patented in 1972 and came into medical use in 1984. side effects section 5.5 of the article doxefazepam in volume 66 of the world health organization's (who) and international agency for research on cancer's (iarc) iarc monographs on the evaluation of carcinogenic risks to humans, an article describing the carcinogenic/toxic effects of doxefazepam on humans and experimental animals, states that there is "inadequate evidence in humans for the carcinogenicity of doxefazepam" and limited evidence in experimental for the carcinogenicity of doxefazepam," and concluded that the overall evaluation of the substance's carcinogenicity to humans is "not classifiable."